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Introduction: Primary lung adenocarcinoma is extremely rare in the
pediatric age group. There have been anecdotal reports of lesions
that are histologically indistinguishable from adult-type pulmonary
adenocarcinoma in young patients after treatment for nonpulmonary
cancers. Herein, we present clinical, histopathologic, and molecular
data on eight such cases.
Methods: Histopathologic evaluation of the tumors was performed
according to the World Health Organization classification. Molecu-
lar studies for EGFR and KRAS mutations were performed on six
patients with sufficient material.
Results: All eight patients were never smokers, four males and four
females. Median age at nonpulmonary cancer diagnosis was 14
years (range, 3–23 years). Pulmonary adenocarcinomas were diag-
nosed at a median age of 15 years (range, 10–24 years); tumors were
0.1 to 2.0 cm in size and in some cases coexisted with metastases
from the original cancer. Retrospective review showed that in at
least three patients, the nodules were radiographically present before
chemotherapy. Of six patients whose tumors were tested for com-
mon EGFR and KRAS mutations, two were positive for the former
and one for the latter. At a median follow-up of 11 months (range,
2–29 months), six patients remained well without lung nodules and
two had additional small, peripheral lung nodules that have not been
biopsied.
Conclusions: Pulmonary lesions found in young patients with
pediatric cancers can be histologically indistinguishable from lung
adenocarcinoma seen in adults, may display typical adenocarcino-
ma-associated mutations of EGFR and KRAS, and may precede the
administration of cytotoxic chemotherapy.
Key Words: Bronchioloalveolar carcinoma, Lung cancer, Adeno-
carcinoma, Secondary malignancies, Osteosarcoma, EGFR, KRAS.
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Primary adenocarcinoma of the lung is exceedingly rare inpediatric patients. In 1982, a review of the 230 pediatric
cases from the English-language literature identified only
47 classifiable as “bronchogenic carcinoma.”1 Although a
small number of sporadic pulmonary adenocarcinomas
have been reported since then,2–5 the preponderance have
been found in conjunction with congenital cystic adeno-
matoid malformations (CCAM) of the lung.6–16 Beyond
this, given the scarcity of cases, it has not been possible to
determine other risk factors for pulmonary adenocarci-
noma in children or adolescents.
In 1988, Travis et al.17 reported two adolescent cancer
patients who had lesions that histologically resembled adult-
type bronchioloalveolar carcinoma (BAC) in the setting of
treatment for other, nonpulmonary malignancies. These lung
lesions were termed “pulmonary nodules resembling bron-
chioloalveolar carcinoma,” despite their identical morphol-
ogy to adult-type BAC, because of the question whether
biologically these represented true lung adenocarcinomas. Since
that initial report, similar lesions have been described in six other
pediatric cancer patients (Supplemental Table 1, Supplemental
Digital Content 1, http://links.lww.com/JTO/A37).18–23 All the
patients had been treated for other pediatric malignancies of
nonpulmonary origin. Until now, it had seemed reasonable to
consider these lesions as secondary malignancies; such a
concept is grounded in the observation that survivors of
childhood cancer have a greater than 14-fold increase in the
relative risk of developing second malignant neoplasms24 and
by the recent observation of renal translocation-related car-
cinomas in children after the administration of cytotoxic
chemotherapy for another cancer.25 Herein, we describe the
largest series of such cases assembled to date, eight patients
between the age of 10 and 24 years with pulmonary lesions
indistinguishable from adult lung adenocarcinomas, includ-
ing invasive tumors as well as BAC (adenocarcinoma in situ)
that were detected either synchronously with, or subsequent
to, treatment for primary pediatric tumors of nonpulmonary
origin.
PATIENTS AND METHODS
Cases were identified in the course of clinical care or
consultation activities by the authors during the 7-year pe-
riod, 2003–2009. In compliance with institutional protocols
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and with guidelines of the Health Insurance Portability and
Accountability Act, a waiver was obtained from the Institu-
tional Review Board of Memorial Sloan-Kettering Cancer
Center (MSKCC) to conduct this retrospective review. Clin-
ical histories, radiologic studies, operative notes, pathologic
analyses, and medical records were evaluated.
Because each of these lesions was discovered inciden-
tally in the course of lung surgery for presumed metastatic
disease, operations were conducted in keeping with published
practices for pediatric patients with lung metastases.26 In
particular, lobectomy and hilar lymph node dissection were
not performed, as pulmonary lymphatic spread is not typical
for the histologies expected to be seen in pediatrics.
Thoracotomies were performed in six of the seven
cases described here, and the histopathologic findings in the
wedge resection specimens were evaluated by pathologists
with special expertise in thoracic oncologic pathology
(M.F.Z, A.L.M., and W.D.T.). In the one patient seen at
MSKCC whose lung resection had been performed elsewhere
(#2), pathology slides from an outside institution were avail-
able for review.
For analysis of EGFR and KRAS mutations, pulmonary
nodules from five cases (patients 3 to 7) were macrodissected
from formalin-fixed, paraffin-embedded sections, and
genomic DNA was extracted. Mutational analysis of EGFR
was performed as published.27 Briefly, EGFR exon 19 de-
letions were detected by length analysis of polymerase
chain reaction (PCR) products. EGFR exon 21 L858R
mutations were analyzed using PCR followed by Sau96I
endonuclease digestion of PCR products. The mutant
EGFR L858R PCR product shows two peaks (87 bp and
173 bp), whereas the digested negative control (wild type)
shows only the 173 bp peak.
In addition, EGFR exon 21 L858R mutations and KRAS
codons 12 and 13 mutations were also analyzed by mass
spectrometry-based genotyping on a Sequenom platform (San
Diego, CA), as described in detail elsewhere.28
RESULTS
Clinical characteristics of the patients are described in
Table 1. All were never smokers. Median age at original
cancer diagnosis was 14 years (range, 3–23 years). Median
age at the diagnosis of pulmonary adenocarcinoma was 15
years (range, 10–24 years). Six of the eight patients had a
primary diagnosis of a bone sarcoma (osteosarcoma, n  5;
chondrosarcoma, n  1); the others had Wilms’ tumor (n 
1) or neuroblastoma (n  1). Individual case summaries are
given below. Histopathology and EGFR and KRAS muta-
tional status are summarized in Table 2. A total of six BACs
were found in five patients and five invasive adenocarcino-
mas in four patients. One patient had two BACs, one patient
had two invasive adenocarcinomas, and one had both a BAC
and an invasive adenocarcinoma. The three tumors that
showed EGFR or KRAS mutations were adenocarcinomas
with an invasive growth pattern.
Case 1
A 7-year-old boy was diagnosed with stage IV Wilms’
tumor and was treated with right radical nephrectomy, regi-
men DD-4A (vincristine, dactinomycin, and doxorubicin),
and 1200 cGy whole lung irradiation. Five years later, pul-
monary relapse was diagnosed, and a fine needle aspiration
confirmed malignant cells. He received chemotherapy ac-
cording to Stratum C of the National Wilms’ Tumor Study-5
consisting of cyclophosphamide, etoposide, and carboplatin.
Thoracoscopic lung resection confirmed metastatic Wilms’
tumor. During cycle 2 of maintenance, he was switched to a
regimen of oral cyclophosphamide and oral etoposide. Com-
puted tomographic (CT) imaging (6 years after initial diag-
nosis) showed possible progression in the lung, and he was
referred to us for thoracotomy (Figure 1A). At surgery, all
suspicious nodules were removed, including a 0.8-cm focus
of metastatic Wilms’ tumor and two separate foci of BAC,
each measuring 1 mm (Figures 1B, C). No further surgery
was carried out. At 11 months after thoracotomy, the patient
developed radiologic evidence of a solitary, enlarging, 6-mm
lung nodule, the histology of which is not known.
Case 2
A 3-year-old girl received multiagent chemotherapy for
an intermediate-grade, stage 3 neuroblastoma according to
Pediatric Oncology Group #9244 using combination vincris-
tine, cisplatin, etoposide, and cyclophosphamide alternating
with vincristine, carboplatin, etoposide, and cyclophospha-
mide. This was changed owing to insufficient response to
vincristine, doxorubicin, and cyclophosphamide, followed by
ifosfamide and etoposide; and finally she received topotecan
(Pediatric Oncology Group #9361), but still no responses in
urine catecholamines were noted. After referral to our center,
gross total resection of the left adrenal mass was performed,
showing ganglioneuroblastoma. She received no subsequent
chemotherapy. Four years later, minute pulmonary nodules
were found. Thoracoscopic biopsy performed at an outside
institution was forwarded to our center for review and was
classified as BAC. No additional treatment was rendered, and
a follow-up CT scan 5 months later showed no progression in
the remaining pulmonary nodules.
Case 3
A 19-year-old man was diagnosed with osteosarcoma
of the right proximal humerus. Calcified, subcentimeter lung
nodules were seen at diagnosis. He received combination
therapy with cisplatin, doxorubicin, and high-dose methotrex-
ate. Seven months into treatment, he underwent thoracotomy
with eight wedge resections. No osteosarcoma was found,
and the majority of the specimens proved to be minute foci of
benign lamellar bone, consistent with metaplastic ossifica-
tion. One wedge resection contained a 0.25-cm nodule of
BAC. No additional chest surgery was performed. At 29
months of follow-up since lung surgery, the patient remained
well; a small number of tiny, highly calcified nodules were
seen on chest CT that have been stable in size and appearance
over 2 years and were thought to represent additional foci of
benign ossification.
Case 4
An 18-year-old man presented with a mass of the right
iliac bone and multiple subcentimeter pulmonary nodules.
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Biopsy of the pelvic mass showed high-grade osteosarcoma
with chondroblastic elements. He received combination cis-
platin, doxorubicin, high-dose methotrexate, and pamidronate
according to an in-house osteosarcoma protocol. At thoracot-
omy 5 months after diagnosis, six suspicious nodules were
resected. None showed osteosarcoma; one was a focus of
BAC measuring 0.26 cm. Without subsequent surgical inter-
vention, the patient has developed no new or progressive
disease 20 months after thoracotomy.
Case 5
A 23-year-old woman was diagnosed with high-grade
osteosarcoma, osteoblastic type, of the proximal humerus.
Chest CT at diagnosis showed a pulmonary nodule (Figure
2A). She received combination cisplatin, doxorubicin, and
high-dose methotrexate. Thoracotomy was performed 8
months into treatment, with wedge resection of the right
middle lobe nodule showing a 0.6 cm, well-differentiated,
acinar-type adenocarcinoma of the lung (Figures 2B–D).
Molecular analysis revealed the tumor to be positive for
EGFR exon 21 L858R mutation by both the PCR/restriction
enzyme assay and Sequenom genotyping (Figure 2E). No
further surgical therapy was performed, and the patient has no
evidence of disease with 11 months of follow-up since
thoracotomy.
Case 6
An 11-year-old girl presented with a lytic lesion of the
distal femur, biopsy of which showed high-grade osteosar-
coma, osteoblastic type. Lung lesions were present on CT
TABLE 1. Clinical Characteristics, Treatments, and Temporal Relationship Between Pulmonary Adenocarcinoma,
Chemotherapy, and Radiotherapy of Patients
Patient
No.
Primary Oncologic
Diagnosis
Age at Primary
Diagnosis Sex
Age at
Thoracotomy
Pulmonary Adenocarcinoma
Preceeded or Followed
Cancer Therapy?
Prior
Chemotherapeutic
Agents
Pulmonary
Irradiation
1 Wilms’ tumor 7 M 13 Unknown Actinomycin-D 1200 cGy
Vincristine
Doxorubicin
Carboplatin
Etoposide
Cyclophosphamide
2 Neuroblastoma 3 F 10a Followed Vincristine None
Cyclophosphamide
Cisplatin
Carboplatin
Doxorubicin
Etoposide
Ifosphamide
Topotecan
3 Osteosarcoma 19 M 20 Unknown Cisplatin None
Doxorubicin
High-dose methotrexate
4 Osteosarcoma 18 M 19 Preceded Cisplatin None
Doxorubicin
High-dose methotrexate
Pamidronate
5 Osteosarcoma 23 F 24 Preceded Cisplatin None
Doxorubicin
High-dose methotrexate
6 Osteosarcoma 11 F 12 Preceded Cisplatin None
Doxorubicin
High-dose methotrexate
L-MTP-PE
7 Chondrosarcoma 14 F 15 Unknown Vincristine None
Doxorubicin
Cyclophosphamide
Ifosfamide
Etoposide
8 Osteosarcoma 14 M 14 Preceded COG AOST0121 None
a Underwent thoracoscopic biopsy at outside institution.
L-MTP-PE, liposomal muramyltripeptide phosphatidylethanolamine; COG, Children’s Oncology Group.
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scanning at diagnosis. She was treated with combination
therapy using cisplatin, doxorubicin, and high-dose metho-
trexate. She also received liposomal muramyltripeptide phos-
phatidylethanolamine. At thoracotomy, the radiographically
identified nodule in the left upper lobe was resected and
found to be a 5-mm focus of moderately differentiated ade-
nocarcinoma, mixed subtype, with acinar and nonmucinous
bronchioloalveolar patterns. Two nodules were found in the
left lower lobe that had not been detected radiographically: a
3-mm acinar subtype adenocarcinoma, and separately, a
1.5-mm focus of metastatic osteosarcoma. The upper lobe
adenocarcinoma was tested for EGFR and KRAS mutations
and found to be negative for both. No additional surgery was
carried out for the pulmonary adenocarcinomas, but staged,
contralateral thoracotomy was performed (in keeping with
our practice to rule out osteosarcoma metastatic to the other
lung). The contralateral lung was free of both osteosarcoma
and adenocarcinoma. She has no evidence of disease 8
months after the initial thoracotomy.
Case 7
A 14-year-old girl presented with a 17-cm mass of the
tibia and a simultaneously diagnosed solitary pulmonary nodule.
Biopsy of the tibial lesion showed mesenchymal chondrosar-
coma. Systemic therapy was administered using combination
vincristine, doxorubicin, cyclophosphamide, ifosfamide, and
etoposide. Wedge resection of the previously identified lung
nodule was performed, revealing metastatic chondrosarcoma. At
thoracotomy, the discovery of additional nodules, not identified
on preoperative imaging, prompted the performance of addi-
tional wedge resections. Findings included one focus of adeno-
carcinoma in the right lower lobe, of mixed subtype with
papillary and bronchioloalveolar patterns, and a separate 2-mm
BAC-like nodule (Figure 3A, B). The focus of mixed type
adenocarcinoma of the right lower lobe was positive for the
KRAS codon 12 G3V mutation by Sequenom genotyping
(Figure 3C). No additional surgery was carried out. With 11
months of follow-up, she remained free of disease.
TABLE 2. Histology and Molecular Pathology of Lung Lesions
Patient No. Histopathology EGFR KRAS
1 Metastatic Wilms’ tumor n/a n/a
Bronchioloalveolar carcinomaa (2 foci of 0.1 cm each)
2 Bronchioloalveolar carcinoma (0.5 cm) n/a n/a
3 Solitary focus of bronchioloalveolar carcinoma (0.25 cm) Negative Negative
Multiple foci of benign metaplastic ossification in lung
4 Bronchioloalveolar carcinoma (0.26 cm) Negative Negative
5 Well-differentiated, acinar-type adenocarcinoma (0.6 cm) L858R mutation Negative
6 Moderately differentiated adenocarcinoma, mixed subtype, with acinar and nonmucinous
bronchioloalveolar patterns (0.5 cm)
Negative Negative
Adenocarcinoma, acinar subtype (0.3 cm)
Metastatic osteosarcoma (0.15 cm)
7 Adenocarcinoma, mixed subtype with papillary and bronchioloalveolar patterns (0.2 cm) Negative G12V mutation
Bronchioloalveolar carcinoma (0.2 cm) in adenocarcinoma
Metastatic mesenchymal chondrosarcoma (0.6 cm)
8 Moderately differentiated adenocarcinoma, mixed subtype, predominantly acinar and
papillary (2.0 cm)
Exon 19 deletion in
adenocarcinoma
Not done
Metastatic osteosarcoma (0.3 cm)
a Bronchioloalveolar carcinoma is currently called adenocarcinoma in situ in the new classification.32
n/a, specimen insufficient or unavailable for molecular study.
FIGURE 1. Case 1. A, Computed tomographic (CT) image of new lung nodule (arrow) that prompted thoracotomy. B and C,
Bronchioloalveolar carcinoma of 1 mm showing crowded cuboidal to columnar cells growing along alveolar walls in a lepidic
fashion, with cellular stratification, overlapping of nuclei, and coarse nuclear chromatin (hematoxylin and eosin; original mag-
nifications, 20 and 40).
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Case 8
A 14-year-old boy was diagnosed with high-grade
osteosarcoma of the right femur. A PET scan at diagnosis
showed, in addition to the primary lesion in the right lower
extremity, a 2.7-cm left lower lobe hypermetabolic mass in
the lung that was considered likely to be a metastasis. He
underwent limb salvage surgery and treatment according to
COG protocol AOST0121 was initiated. At 3 months, a chest
CT revealed the left lower lobe somewhat reduced in size (1.6
cm) as well as some small nodules in the lingual and right
lung base. Thoracotomy was performed 5 months into treat-
ment, with wedge resection of two lingular nodules and left
lower lobectomy. The lingular lesions were a calcified nodule
and a nodule with osteoid, consistent with treated osteosar-
coma. The left lower lesion was a 2.0 cm, predominantly
acinar-type adenocarcinoma of the lung (Figure 4) immuno-
FIGURE 2. Case 5. A, Suspicious density seen on CT scan in the right middle lobe of the lung at the time of diagnosis of os-
teosarcoma of the humerus. B and C, Invasive adenocarcinoma of the right middle lobe of the lung. Note the presence of in-
vasive glands with fibrotic stroma and sharp demarcation between the tumor cells and the normal pulmonary parenchyma
(hematoxylin and eosin; original magnifications, 10 and 40). D, Immunohistochemical stain for TTF-1. This photomicro-
graph shows that the invasive glands are positive for TTF-1, thus confirming a pulmonary origin for this adenocarcinoma. E,
Mass spectrometry-based genotyping for EGFR exon 21 L858R mutation on Sequenom platform confirming the presence of
L858R mutation. The germline peak is indicated by an asterisk and the mutant peak by an arrow. CT, computed tomography;
TTF, thyroid transcription factor-1.
FIGURE 3. Case 7. A, Right lower lobe adenocarcinoma, mixed subtype with papillary and bronchioloalveolar patterns (he-
matoxylin and eosin; original magnification, 40). B, Bronchioloalveolar carcinoma-like nodule in the right middle lobe not
seen on preoperative CT scan (hematoxylin and eosin; original magnification, 40). C, Sequenom genotyping assay showing
the presence of G 3 T mutation at position 35 in KRAS codon 12 (G12V mutation) in the mixed-type adenocarcinoma of the
right lower lobe. The germline peak is indicated by an asterisk and the mutant peak by an arrow. CT, computed tomography.
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reactive for thyroid transcription factor-1 and CK7 and neg-
ative for CDX2 and CK20. Molecular analysis revealed the
lung adenocarcinoma to be positive for EGFR exon 19
deletion. The patient is at only 2 months postthoracotomy.
EGFR and KRAS Mutations
Table 2 summarizes the findings with respect to EGFR
and KRAS mutations. Of the six patients whose tumors were
tested, three were found negative for the common mutations
of both EGFR and KRAS. The adenocarcinomas in patients 5
and 8 were positive for mutation of EGFR. In patient 7, the
adenocarcinoma showed a G12V mutation in KRAS.
Temporal Relationship to Chemotherapy
Temporal relationship between the administration of
chemotherapy and the finding of adenocarcinoma in the lung
is shown in Table 1. In at least four of the eight patients,
pulmonary nodules that later proved to be adenocarcinoma
were detected by imaging before the administration of poten-
tially mutagenic chemotherapy.
Clinical Follow-Up
Additional surgery related to the pulmonary adenocar-
cinomas, such as lobectomy or hilar lymph node dissection,
was not carried out in any of the patients. Additional chemo-
therapy, beyond the substantial multiagent regimens already
prescribed for the nonpulmonary primary cancers, was not
administered. Median duration of follow-up is 11 months
(range, 5–29 months) (Table 3). During this follow-up, two
patients had persistent or recurrent radiographic evidence of
small lung nodules (histology unknown). Five patients re-
mained free of disease with respect to both primary tumors.
DISCUSSION
Our analysis of this series indicates that the tumors
previously described as BAC-like nodules found in pediatric
cancer patients are (1) adenocarcinomas with a spectrum of
BAC (adenocarcinoma in situ) and invasive histologic pat-
terns and (2) may be present before administration of che-
motherapy for the underlying malignancy and therefore are
not always or necessarily secondary malignancies, as had
been previously believed. Specifically, patients 4, 5, 6, and 8
had radiographic evidence of pulmonary nodules at the time
of their original cancer diagnosis before any treatment. In two
patients, these nodules proved to be adenocarcinomas, and in
two cases, there was adenocarcinoma coexisting with lung
metastases from osteosarcoma. The observation of eight
young patients with incidental pulmonary adenocarcinomas
raises the possibility that the contemporaneous presence of a
primary pediatric malignancy and pulmonary adenocarci-
noma may reflect more than coincidence.
Our study clearly documents that invasive patterns of
adenocarcinoma occur in the setting of pediatric cancer pa-
tients in addition to BAC/adenocarcinoma in situ. Three of
the seven patients had areas of invasion in addition to the
BAC/adenocarcinoma in situ. How to properly classify the
lung tumors with BAC/adenocarcinoma in situ histology in
young cancer patients has been problematic since their orig-
inal description in 1988, because of their noninvasive growth
pattern, their presentation as incidental findings, and the
young age of the patients. For these reasons in 1988, we
(W.D.T.) were reluctant to call these tumors BAC and qual-
ified the terminology for these cases as “BAC-like nodule.”
However, in 1995, it was recognized that patients with small
solitary adenocarcinomas with a pure BAC histology in the
absence of any invasion have a 100% 5-year survival.29 This
led to a strict redefinition of the use of the term BAC by 1999
World Health Organization classification as a noninvasive
tumor with pure lepidic growth, and this concept was main-
tained in the 2004 classification.30,31 Furthermore, the excel-
lent survival for small solitary BACs has been validated in
multiple subsequent studies, so these tumors are currently
being proposed to be called “adenocarcinoma in situ” in the
next classification of lung adenocarcinoma.32 Notably, how-
ever, we found invasive patterns of lung adenocarcinoma in
four of the eight patients in this study.
FIGURE 4. Case 8. Left lower lobe adenocarcinoma, mixed
subtype with predominant acinar pattern (hematoxylin and
eosin; original magnification, 40). This tumor contained an
EGFR mutation (exon 19 deletion) (see text). EGFR, epider-
mal growth factor receptor.
TABLE 3. Clinical Outcomes
Patient
No.
Follow-Up
Since
Thoracotomy
(mo)
Additional
Treatment for
Pulmonary
Adenocarcinoma
Disease Status
of Primary
Tumor
Disease Status
of Pulmonary
Adenocarcinoma
1 11 None AWD AWDa
2 5 None NED AWD
3 29 None NED NED
4 20 None NED NED
5 11 None NED NED
6 8 None NED NED
7 11 None NED NED
8 2 None NED NED
a Patient 1 has a solitary enlarging lung nodule at last follow-up, the histology of
which is not yet determined.
AWD, alive with disease, NED, no evidence of disease.
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Pediatric cancer patients undergo lung imaging and
thoracotomy at a rate vastly exceeding that of healthy chil-
dren, so it may be argued that incidentally found lung lesions
such as these may have a different natural history from usual
adult lung cancer. However, incidental pulmonary adenocar-
cinomas have so far not been reported among children un-
dergoing workup and surgery for benign etiologies such as
trauma, bleb disease, or empyema. There is, however, a
well-established association between CCAM and pulmonary
adenocarcinoma. However, CCAM-associated adenocarcino-
mas are typically mucinous lesions and likely stem from a
different underlying molecular pathway. Mucinous BACs are
associated with higher frequencies of KRAS mutations com-
pared with nonmucinous tumors,33 and mucinous carcinomas
seen in association with CCAMs have been shown to exhibit
loss of heterozygosity at the p16INK4 locus.34 Such lesions
should be contrasted with the nonmucinous lesions exhibited
by the patients in this series, as well as by most of the pediatric
cancer patients previously reported to have developed pulmo-
nary adenocarcinoma (Supplemental Table 1, Supplemental
Digital Content 1, http://links.lww.com/JTO/A37). The coexist-
ence of primary pediatric malignancies and early pulmonary
adenocarcinomas as seen here may reflect the presence of an
underlying germline predisposition or a common carcino-
genic exposure. Additional cases may help to define this, but
we should note that none of the patients had family histories
suggestive of known familial cancer syndromes. In this re-
gard, a locus associated with increased risk of lung cancer in
never smokers has recently been reported.35
To our knowledge, mutations in EGFR or KRAS have
not been previously documented in pediatric pulmonary ad-
enocarcinoma. The mutational analysis presented here pro-
vides a starting point for elucidating the genetic alterations
driving lung neoplasia in this clinical setting. Two of the
eight with predominantly acinar histology displayed the
EGFR mutations, and another mixed subtype adenocarci-
noma showed the KRAS G12V mutation. All three of these
tumors had an invasive growth pattern. This mutation rate is
not statistically different from the incidence of such muta-
tions among adult North American lung cancer patients,
where 20% of lung adenocarcinomas harbor mutations of
EGFR36 and about 25 to 30% contain KRAS mutations.37,38
The EGFR mutations have a negative association with smok-
ing, whereas KRAS G12V lacks a clear negative or positive
association with smoking.39 The presence of these mutations,
in addition to the histology, provides further evidence that these
tumors are clonal neoplasms, rather than reactive atypical pneu-
mocyte proliferations. Finally, Park et al40 recently reported two
adolescents with lung adenocarcinoma without a prior or con-
current pediatric cancer who both died of their disease.
After surgical resection, the appropriate follow-up
treatment for an incidentally discovered, subcentimeter pul-
monary adenocarcinoma is not defined in pediatrics. The
principles in surgery for lung cancer are founded on data from
adults with tumors large enough to be detected on chest
radiographs, rather than the minute tumors found by CT
scanning or by palpation at the time of thoracotomy.41,42 The
surgical management of incidentally discovered pulmonary
adenocarcinomas less than 2 cm in size has been significantly
revisited in recent years by Rusch and others, with an em-
phasis on sublobar resection.43–49 Despite the persistence of
pulmonary nodules of unknown histology in two of our
patients, we did not observe definite malignant behavior such
as recurrence or metastases in any of our cases.
Seven of the eight patients presented here were com-
prehensively discussed at a multidisciplinary tumor board. In
each case, the consensus was reached that preservation of
pulmonary parenchyma and of lung function were overriding
priorities, especially in light of the potential need for addi-
tional pulmonary metastatectomies in the future, given these
patients’ underlying high-grade malignancies. Consequently,
we have chosen close surveillance and have specifically
avoided repeat thoracotomies for lobectomies or hilar lymph
node dissections. No additional chemotherapy was thought to
be warranted. Most of the patients were still in the process of
receiving aggressive combination chemotherapy regimens for
their primary tumors when the diagnosis of pulmonary ade-
nocarcinoma was made. Continued follow-up and molecular
studies will be needed to more definitively comment on the
success of this approach.
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